A Phase Ib study of ruxolitinib + gemcitabine ± nab-paclitaxel in patients with advanced solid tumors

PURPOSE: Aberrant activation of the Janus-associated kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is associated with increased malignant cell proliferation and survival. This Phase Ib study evaluated ruxolitinib, a potent JAK1/2 inhibitor, in combination with gemcitab...

Descripción completa

Detalles Bibliográficos
Autores principales: Bauer, Todd M, Patel, Manish R, Forero-Torres, Andres, George, Thomas J, Assad, Albert, Du, Yining, Hurwitz, Herbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5935192/
https://www.ncbi.nlm.nih.gov/pubmed/29750040
http://dx.doi.org/10.2147/OTT.S157331

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5935192/
https://www.ncbi.nlm.nih.gov/pubmed/29750040
http://dx.doi.org/10.2147/OTT.S157331

Ejemplares similares